Trial · NCT04475588
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Sinus tachycardia | Cardiac disorders | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Hypothyroidism | Endocrine disorders | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Hypothyroidism | Endocrine disorders | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Constipation | Gastrointestinal disorders | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Constipation | Gastrointestinal disorders | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Chills | General disorders | Arm A - Itolizumab + BSC | 5 | 22 | 6 |
| other | Chills | General disorders | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Urinary tract infection | Infections and infestations | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Urinary tract infection | Infections and infestations | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Alanine aminotransferase increased | Investigations | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Alanine aminotransferase increased | Investigations | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Fibrin D dimer increased | Investigations | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Fibrin D dimer increased | Investigations | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Low density lipoprotein increased | Investigations | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Low density lipoprotein increased | Investigations | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
| other | Lymphocyte count decreased | Investigations | Arm A - Itolizumab + BSC | 11 | 22 | 11 |
| other | Lymphocyte count decreased | Investigations | Arm B - Best Supportive Care (BSC) | 2 | 10 | 2 |
| other | Non-high-density lipoprotein cholesterol increased | Investigations | Arm A - Itolizumab + BSC | 1 | 22 | 1 |
| other | Non-high-density lipoprotein cholesterol increased | Investigations | Arm B - Best Supportive Care (BSC) | 0 | 10 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04475588/events